Christine Des Rosiers

Director of the Montreal Heart Institute Metabolomics Platform and Professor of Nutrition & Biochemistry at Université de Montréal.

Metabolomics at the MHI: Focusing on biomarker discovery-based biomedical research

 Emerging technologies in metabolomics – the most recent addition to the “omics” disciplines – offer a means to measure thousands of low molecular weight compounds from any cell, tissue or body fluid. This provides a global view of alterations in metabolic pathways induced by a given perturbation, whether resulting from a gene mutation or disease onset. There are, however, numerous challenges and issues, which need to be taken into account for the successful application of metabolomics to disease biomarker discovery particularly in the setting of large cohort clinical studies integrating other omics data. This presentation will illustrate how we tackle these challenges and provide an overview of on-going research activities.

Biosketch

Dr. Christine Des Rosiers is director of the Montreal Heart Institute Metabolomics Platform and Professor of Nutrition & Biochemistry at Université de Montréal. She has 25 years of research experience in metabolic investigations using stable isotopes and mass spectrometric-based methodology as applied to the field of nutrition and heart research. She is currently leading several metabolomic investigations as part of funded initiatives on the Leigh Syndrome French Canadian Type: Translating gene discovery into treatments for patients, MHI Biomarker Discovery Program applied to cardiovascular diseases and the multidisciplinary personalized medicine project on inflammatory bowel diseases. She is a founding member and recently appointed president of the Society for Heart and Vascular Metabolism. She is a member of the International Scientific Committee of the INRA’s MetaboHub Infrastructure, and an Associate Editor of the journal Am. J. Physiol. Heart & Circ. Physiol.

Date
Date(s) - March 15, 2016
7:00 pm - 10:00 pm

Emplacement / Location
Morris and Rosalind Goodman Agora